Baillie Gifford & Co. Lowers Position in Cardlytics, Inc. (NASDAQ:CDLX)

Baillie Gifford & Co. lowered its position in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 91.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,413 shares of the company's stock after selling 516,983 shares during the period. Baillie Gifford & Co. owned 0.10% of Cardlytics worth $187,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Cardlytics by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock worth $3,371,000 after acquiring an additional 73,484 shares in the last quarter. RBF Capital LLC lifted its stake in Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company's stock worth $1,562,000 after purchasing an additional 369,620 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Cardlytics by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company's stock valued at $1,249,000 after purchasing an additional 11,388 shares in the last quarter. GSA Capital Partners LLP increased its stake in Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company's stock valued at $1,223,000 after purchasing an additional 354,474 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Cardlytics by 56.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company's stock valued at $1,016,000 after purchasing an additional 113,966 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CDLX. Craig Hallum upgraded shares of Cardlytics from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 6th. Needham & Company LLC restated a "hold" rating on shares of Cardlytics in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $6.92.

Cardlytics Stock Performance

Shares of CDLX traded down $0.27 during mid-day trading on Friday, reaching $2.69. 2,276,722 shares of the company's stock were exchanged, compared to its average volume of 929,168. The business's fifty day simple moving average is $3.44 and its 200-day simple moving average is $3.72. Cardlytics, Inc. has a 52-week low of $2.67 and a 52-week high of $20.52. The stock has a market capitalization of $136.71 million, a PE ratio of -0.44 and a beta of 1.54. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Insider Buying and Selling

In related news, CEO Amit Gupta sold 46,857 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the transaction, the chief executive officer now owns 418,637 shares in the company, valued at $1,423,365.80. The trade was a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Alexis Desieno sold 8,854 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $32,494.18. Following the sale, the chief financial officer now directly owns 121,976 shares of the company's stock, valued at approximately $447,651.92. This represents a 6.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 111,454 shares of company stock worth $391,864 in the last 90 days. Company insiders own 4.40% of the company's stock.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.